logo

Seelos Therapeutics, Inc (SEEL)



Trade SEEL now with
  Date
  Headline
5/28/2020 7:06:47 AM Seelos Therapeutics Begins Preclinical Study Of SLS-004 In Parkinson's Disease
5/4/2020 8:12:09 AM Seelos Therapeutics Receives Notice Of Allowance For Additional US Patent For Trehalose
4/8/2020 9:34:11 AM Seelos Expects To Release Addl Safety Data On Phase I Studies Of SLS-002 In Q2
3/11/2020 9:03:06 PM Seelos Therapeutics Announces Pricing Of Underwritten Public Offering Of 7.50 Mln Shares At $0.60/shr
3/11/2020 8:14:21 AM Seelos Therapeutics Announces EMA Guidance To Design An Open-Label Pivotal Study For SLS-005 In Sanfilippo Syndrome
3/6/2020 8:08:29 AM Seelos Therapeutics Receives Notice Of Allowance From USPTO For Composition Of Matter Patent For SLS-007
1/28/2020 8:20:17 AM Seelos Therapeutics Announces Update To Its Parkinson’s Disease Program SLS-007
1/22/2020 7:34:58 AM Seelos Therapeutics Updates Regarding Development Programs For SLS-005
1/10/2020 7:36:19 AM Seelos Therapeutics Announces Interim Data From Phase I Study Of Intranasal Racemic Ketamine (SLS-002)
1/6/2020 8:15:06 AM Seelos Therapeutics Announces Scheduling Of A Type C Meeting With FDA In March 2020
8/23/2019 9:04:45 AM Seelos Therapeutics Announces Pricing Of $6.7 Mln Registered Direct Offering
7/17/2019 9:09:36 AM Seelos Submits IND Application For Initiation Of Phase IIb/III Study Of SLS-005
1/24/2019 8:05:01 AM Seelos Therapeutics Completes Merger With Apricus Biosciences
1/15/2019 7:00:58 AM Apricus Biosciences Stockholders Approve Merger With Seelos Therapeutics; Merger To Close In January 2019
12/10/2018 7:02:04 AM Apricus Biosciences Reminds Shareholders To Vote Before Special Meeting On December 14, 2018
10/31/2018 4:29:31 PM Apricus Biosciences Loss/share $0.12 Vs. Loss $0.29 Year Ago